- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2020-09-01
2021-12-01
2021-12-30
600
NCT04549064
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital Xi'an Jiaotong University
OBSERVATIONAL
Biomarkers of Pancreatic Cancer and New Way to Detection
Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.
Serum was collected ： pancreatic cancer : healthy control =200:200 Clinical data were collected: age, gender, diagnosis, cancer stage, CA199 level at initial diagnosis, histopathological type, etc. The informed consent of the subjects was obtained before the study, and all experimental procedures were approved by ethics. Draw a summary table of patient characteristics. The level of AREG was detected by ELISA kit and compared with CA199. Fabrication of a new electrochemical biosensor. Characterization of sensor performance.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2020-09-09 | N/A | 2021-08-20 |
2020-09-14 | N/A | 2021-08-23 |
2020-09-16 | N/A | 2021-08 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : Patients with pancreatic cancer Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging ma | DIAGNOSTIC_TEST: diagnosis of pancreatic cancer
|
| : Healthy Control healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors. | DIAGNOSTIC_TEST: diagnosis of pancreatic cancer
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Diagnosis of Pancreatic Cancer | Diagnosis based on the concentration of serum biomarkers | through study completion, an average of 1 year |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: wang qi, master Phone Number: 0086-15991439170 Email: wangqill1024@163.com |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
20 Years
Accepts Healthy Volunteers:
1
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
